ClinicalTrials.Veeva

Menu

ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)

A

Acute Leukemia French Association

Status and phase

Withdrawn
Phase 3

Conditions

Acute Myeloid Leukemia

Treatments

Drug: AZACITIDINE (VIDAZA)
Drug: Vesanoid (ATRA)
Drug: CYTARABINE

Study type

Interventional

Funder types

Other

Identifiers

NCT01067274
ALFA-0703 Study - P060205

Details and patient eligibility

About

A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid (ATRA) in Combination with Induction Chemotherapy, or Azacitidine and Idarubicin as salvage therapy and Idarubicin with Cytarabine or Azacitidine as Maintenance Therapy in Older Patients with Acute Myeloblastic Leukemia (AML).

To compare the outcome of elderly patients with newly-diagnosed AML treated with standard induction chemotherapy and post-remission therapy, in only patients in CR, with either azacitidine or cytarabine combined to idarubicin +/- ATRA and salvage therapy with azacitidine combined to idarubicin +/- ATRA.

Full description

Induction therapy :

First randomization (R1) at baseline : ATRA versus no ATRA.

Salvage therapy :

No conventional salvage therapy is planned. Patients who will not achieve CR, according to IWG criteria after induction will be treated with 3 courses of azacitidine and idarubicin +/- ATRA combination, if eligible for further treatment.

Followed by 3 identical courses and 6 courses of maintenance by azacitidine alone to be delivered every 28 days, in those patients reaching CR or PR after 3 courses (evaluation of response from 28 to 56 days from course 3).

Randomization R2: type of maintenance:

Response to induction will be evaluated 2 weeks after myeloid recovery, just before first consolidation course, due use of to pegfilgrastim, lenograstim or filgrastim during induction.

Responses will be classified according to the Revised Recommendations of the IWG for AML.

Patients in CR only will be subjected to a second randomization R2 as follows 6 courses of combined chemotherapy, will be delivered as outpatients, ATRA according to R1 randomization.

Sex

All

Ages

65 to 79 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Aged of 65 to 79 years
  2. With a morphologically proven diagnosis of AML according to WHO classification either de novo or AML with "myelodysplasia related changes"
  3. Not previously treated for AML
  4. Signed informed consent.

Exclusion criteria

  1. APL in the WHO classification.
  2. Ph1-positive AML or prior Ph1-positive disease
  3. AML evolving from a prior MPN in the WHO 2008 classification.
  4. Prior treatment with chemotherapy or radiotherapy for another tumor
  5. Prior tumor, if not stable for at least two years, except in-situ carcinoma and skin carcinoma
  6. Prior advanced malignant hepatic tumor
  7. ECOG Performance Status Score > 2
  8. Creatinine level more than 2x's the upper limit of the normal range (ULN) at the laboratory where the analysis was performed, except if AML-related.
  9. Total serum bilirubin more than 2x's the ULN at the laboratory where the analysis was performed, except if AML-related.
  10. AST (SGOT) or ALT (SGPT) more than 2.5x's the ULN at the laboratory where the analysis was performed, except if AML-related
  11. LVEF less than.55 or equivalent by doppler echocardiography
  12. Known intolerance to Azacitidine, mannitol, retinoids
  13. Positive serum test for HIV and HTLV-1
  14. NYHA Grade 3/4 cardiac disease .
  15. Severe infection at inclusion time.
  16. Psychiatric disease or an history of non-compliance to medical regimens or patients considered potentially unreliable.
  17. Absence of health care insurance (affiliation à un régime de Sécurité Sociale)
  18. Participation to any study requiring informed consent

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

0 participants in 6 patient groups

R1 Arm A : ATRA
Experimental group
Description:
Idarubicin: 9 mg/m2/d D1 to D4 Cytarabine : 200 mg/m2/d Continuous IV from D1 to D7 Peg-filgrastim : 6 mg SC D9 or filgrastim 5ug/kg/d SC or lenograstim 263ug/d IV 30mn, both from D9 to myeloid recovery(PMN \>1G/l over 2 days at minimum All-trans retinoic acid (ATRA): 45mg/m2/day in two divided doses from D8 to D28
Treatment:
Drug: Vesanoid (ATRA)
R1 Arm B : no ATRA
No Intervention group
Description:
Idarubicin: 9 mg/m2/d D1 to D4 Cytarabine : 200 mg/m2/d Continuous IV from D1 to D7 Peg-filgrastim : 6 mg SC D9 or filgrastim 5ug/kg/d SC or lenograstim 263ug/d IV 30mn, both from D9 to myeloid recovery(PMN \>1G/l over 2 days at minimum
R2 Arm 1A : AZACITIDINE and ATRA
Experimental group
Description:
Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5 All-trans retinoic acid (ATRA): 45mg/m2/d in two divided doses from D8 to D21
Treatment:
Drug: Vesanoid (ATRA)
Drug: AZACITIDINE (VIDAZA)
R2 Arm 1B : AZACITIDINE and No ATRA
Experimental group
Description:
Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5
Treatment:
Drug: AZACITIDINE (VIDAZA)
R2 Arm 2A : ATRA
Experimental group
Description:
Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5 All-trans retinoic acid (ATRA): 45mg/ m2/d in two divided doses from D8 to D21
Treatment:
Drug: Vesanoid (ATRA)
Drug: CYTARABINE
R2 Arm 2B : no ATRA
Experimental group
Description:
Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5
Treatment:
Drug: CYTARABINE

Trial contacts and locations

26

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems